Virax Biolabs Group Ltd
NASDAQ:VRAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Asia Mineral JSC
VN:AMC
|
VN |
|
Oceanpal Inc
NASDAQ:SVRN
|
GR |
|
SJW Group
NASDAQ:HTO
|
US |
|
Bytes Technology Group PLC
LSE:BYIT
|
UK |
ROA
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Peer Comparison
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| UK |
V
|
Virax Biolabs Group Ltd
NASDAQ:VRAX
|
1.3m USD |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
108.8B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
63.2B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
62.4B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
50.5B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
30.6B AUD |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.7B CNY |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.3B CNY |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.3B HKD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
Market Distribution
| Min | -1 565.9% |
| 30th Percentile | -0.1% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 336% |
Other Profitability Ratios
Virax Biolabs Group Ltd
Glance View
Virax Biolabs Group Ltd is a GB-based company operating in Health Care Providers & Services industry. Virax Biolabs Group Limited is a biotechnology company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.
See Also
ROA is calculated by dividing the Net Income by the Avg Total Assets.
The current ROA for Virax Biolabs Group Ltd is -74.5%, which is above its 3-year median of -108.4%.
Over the last 2 years, Virax Biolabs Group Ltd’s ROA has increased from -110.7% to -74.5%. During this period, it reached a low of -195.7% on Sep 30, 2023 and a high of -74.5% on Sep 30, 2025.
